Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

AMO Adds Glaucoma Device, Fills Cataract Line With $450 Mil. Pfizer Eye Unit

This article was originally published in The Gray Sheet

  • News

Executive Summary

Advanced Medical Optics' purchase of Pfizer's surgical ophthalmology business bolsters its cataract surgery portfolio by adding viscoelastics and expanded intraocular lens (IOL) offerings

You may also be interested in...



Boston University-Raised Solx Will Leave The Nest With DeepLight Launch

Solx plans to formally begin commercial operations when it launches the DeepLight glaucoma treatment system at the International Glaucoma Symposium in Cape Town, South Africa, March 30-April 2

Boston University-Raised Solx Will Leave The Nest With DeepLight Launch

Solx plans to formally begin commercial operations when it launches the DeepLight glaucoma treatment system at the International Glaucoma Symposium in Cape Town, South Africa, March 30-April 2

AMO To Surround Eye Surgeons With Refractive Offerings After Visx Purchase

Advanced Medical Optics' acquisition of pure-play LASIK manufacturer Visx will enable the combined entity to more effectively market laser eye surgery to physicians performing both refractive and cataract procedures

Table

View full table

Related Content

Medtech Insight
Medtech Insight
Tags:
Latest Headlines

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

See All
UsernamePublicRestriction

Register

MT020100

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By